Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942136 · ClinicalTrials.gov registry record · Phase 1
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00942136 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT00942136, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a high fat meal impacts the blood levels of GSK1349572. In addition, the safety, tolerability, and pharmacokinetics of single supratherapeutic (high) dose of GSK1349572 will be evaluated.
Interventions
- DRUG Placebo
- DRUG Omeprazole
- DRUG GSK1349572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942136
The ClinicalTrials.gov registry entry for NCT00942136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00942136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942136 about?
NCT00942136 is a clinical study titled "GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study". GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a...
What is the current status of trial NCT00942136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-07. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00942136?
The interventions under investigation include: Placebo (DRUG), Omeprazole (DRUG), GSK1349572 (DRUG).
Who is sponsoring clinical trial NCT00942136?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.